Fuller & Thaler Asset Management
MDGL icon

Fuller & Thaler Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Fuller & Thaler Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-12,434
Closed -$2.75M – 624
2013
Q3 		$2.75M Buy
+12,434
New +$2.65M 0.16% 182

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fuller & Thaler Asset Management's MDGL Position: Q4 2013 in Review

Fuller & Thaler Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2013, closing a stake of 12,434 shares — an estimated $2.75M sold.

Fuller & Thaler Asset Management first reported a position in MDGL in Q3 2013 and held it in 1 quarter. The position peaked at $2.75M in Q3 2013. 77 funds tracked by Wall St. Rank hold MDGL as of Q4 2013.

  • Fuller & Thaler Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 12,434 Madrigal Pharmaceuticals shares in Q4 2013, an estimated $2.75M.
  • Fuller & Thaler Asset Management first reported a position in Madrigal Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Fuller & Thaler Asset Management's Madrigal Pharmaceuticals position peaked at $2.75M in Q3 2013.
  • 77 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2013.

Based on Fuller & Thaler Asset Management's 13F filing for Q4 2013, filed 13 Feb 2014.